^
    1d
    N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, Northwestern University
    New P1 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    2d
    ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival. (PubMed, medRxiv)
    ATRX status may serve as a potential biomarker for prognosis and therapeutic stratification. Future clinical trials investigating epigenetic therapies could offer novel treatment strategies for ATRX-deficient sarcomas.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler)
    4d
    Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma. (PubMed, Cancer Res Commun)
    A palbociclib lead-in prior to retifanlimab had a high rate of immune-related toxicities. Correlative analyses identified changes in tumor and immune cells attributable to treatment. A study of concurrent dosing of the combination is ongoing.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)
    |
    Ibrance (palbociclib) • Zynyz (retifanlimab-dlwr)
    4d
    Paratesticular liposarcomas: A rare but crucial diagnosis. Case series and review of literature. (PubMed, Cent European J Urol)
    Emerging therapies targeting the MDM2 and CDK4 pathways show promise for advanced or recurrent cases. This report highlights the complexity of diagnosing and managing paratesticular liposarcomas, underlining the importance of multimodal approaches for improved outcomes.
    Review • Journal
    |
    CDK4 (Cyclin-dependent kinase 4)
    6d
    Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (PubMed, World J Surg Oncol)
    This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-H • PD-L1 negative
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • pazopanib • Halaven (eribulin mesylate)
    8d
    SOX9, GATA3, and GATA4 Overexpression in Liposarcomas: Insights into the Molecular Biology of Adipocytic Sarcomas. (PubMed, Int J Mol Sci)
    Integration of these molecular markers into diagnostic and prognostic workflows may enhance subtype characterization and inform targeted therapeutic strategies. Further studies in larger cohorts are warranted to validate these biomarkers and explore their mechanistic interplay in liposarcoma pathogenesis.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • GATA3 (GATA binding protein 3)
    8d
    Dehydroascorbic Acid Induces Cell Death in Sarcoma Stem Cells Under bFGF-Mediated Stemness-Supporting Conditions. (PubMed, Antioxidants (Basel))
    Also, investigation of somatic mutations of oncogenes and tumor suppressors revealed that in liposarcoma and rhabdomyosarcoma, there are mutations that induce proliferative signals. These proliferative signals, joined with bFGF in the presence of DHA, do not lead to proliferation but instead cause cell death.
    Journal
    |
    FGF (Fibroblast Growth Factor)
    9d
    Clinicopathological Implications of Maspin, CD8, and PD-L1 Expression in Liposarcomas. (PubMed, Curr Issues Mol Biol)
    Despite low overall expression rates, PD-L1 could serve as a prognostic biomarker and a potential target for immunotherapeutic strategies in liposarcomas. Further studies are necessary to standardize PD-L1 assessment and explore effective immunotherapy approaches for these tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • PD-L1 IHC 28-8 pharmDx
    11d
    Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032. (PubMed, medRxiv)
    Matrix-remodeling stromal and epithelial-like sarcoma cell programs were associated with worse outcomes and diminished with pembrolizumab and RT. Our findings identify different mechanisms of response to pembrolizumab in localized, high-risk UPS/LPS and suggest that sarcoma TME signatures may identify patients most likely to benefit from adding pembrolizumab to preoperative RT.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab)
    14d
    TQB3616-II-03: TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P2, N=26, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=118 --> 26 | Trial completion date: Dec 2024 --> Sep 2025 | Not yet recruiting --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    culmerciclib (TQB3616)
    14d
    Criteria for MDM2 fluorescence in situ hybridization testing in the diagnosis of well-differentiated adipocytic neoplasms: a retrospective utilization review of 1151 cases. (PubMed, Virchows Arch)
    The sensitivity of Clay criteria plus nuclear atypia for ALT/WDL was 97.8%, while specificity was 62.7%. We conclude that it is safe to defer MDM2 FISH in well-differentiated fatty tumors not meeting Clay criteria and lacking nuclear atypia.
    Retrospective data • Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    18d
    Integrating machine learning and molecular dynamics simulation to decipher the molecular network of dioxin-associated liposarcoma. (PubMed, Sci Rep)
    The selective HTR2A receptor antagonist ketanserin has the potential to alleviate this toxicological impact. Our study presents an efficient, cost-effective toxicological analysis using network toxicology, offering new insights into dioxin-associated liposarcoma.
    Journal
    |
    CDH3 (Cadherin 3) • MMP14 (Matrix Metallopeptidase 14) • ADORA2B (Adenosine A2b Receptor) • HTR2A (5-Hydroxytryptamine Receptor 2A)